Eye donation from palliative and hospice care contexts: the EDiPPPP mixed-methods study.

Autor: Long-Sutehall T; School of Health Sciences, University of Southampton, Southampton, UK., Bracher M; School of Health Sciences, University of Southampton, Southampton, UK., Mollart S; West Suffolk Hospital NHS Foundation Trust, Suffolk, UK., Wale J; Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, UK.

Publikováno v: Health and social care delivery research [Health Soc Care Deliv Res] 2023 Nov; Vol. 11 (20), pp. 1-159.

Spengler J, Bracher M: Toxicological tests and health risk assessment of oxidative hair dye mixtures. Cosmetics & Toiletries 105:67-76, 1990

Autor: Mary C. Martini

Publikováno v: Dermatitis. 1:256

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::358462c13324fae8e1e8e6c4940ecd0e
https://doi.org/10.1097/01206501-199012000-00017

A concept elicitation study to understand the relationship between sleep and pain in rheumatoid arthritis and axial spondyloarthritis.

Autor: Raymond K; QualityMetric Incorporated, Johnston, RI, USA., Chen WH; GSK, Global Value Evidence and Outcomes, 1250 South Collegeville Road, Building 4, 4th floor, Collegeville, PA, 19426, USA. wen-hung.x.chen@gsk.com., Bracher M; GSK, Global Value Evidence and Outcomes, Stevenage, UK., Foster A; QualityMetric Incorporated, Johnston, RI, USA., Lovley A; QualityMetric Incorporated, Johnston, RI, USA., Saucier C; QualityMetric Incorporated, Johnston, RI, USA., Jackson K; QualityMetric Incorporated, Johnston, RI, USA., McDermott EJ; GSK, Real-World Study Delivery, Stevenage, UK.

Publikováno v: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2024 Feb; Vol. 33 (2), pp. 373-385. Date of Electronic Publication: 2023 Oct 27.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).

Autor: Fleischmann RM; Department of Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA rfleischmann@arthdocs.com.; Metroplex Clinical Research Center, Dallas, Texas, USA., van der Heijde D; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Strand V; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, USA., Atsumi T; Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., McInnes IB; College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK., Takeuchi T; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine Graduate School of Medicine, Shinjuku-ku, Japan.; Saitama Medical University, Saitama, Japan., Taylor PC; Botnar Research Centre, University of Oxford, Oxford, UK., Bracher M; GSK, Stevenage, UK., Brooks D; GSK, Collegeville, Pennsylvania, USA., Davies J; GSK, Stevenage, UK., Goode C; GSK, Brentford, UK., Gupta A; GSK, Stevenage, UK., Mukherjee S; GSK, Collegeville, Pennsylvania, USA., O'Shea C; GSK, Dublin, Ireland., Saurigny D; GSK, Stevenage, UK., Schifano LA; GSK, Durham, North Carolina, USA., Shelton C; GSK, Collegeville, Pennsylvania, USA., Smith JE; GSK, Stevenage, UK., Wang M; GSK, Brentford, UK., Wang R; GSK, Collegeville, Pennsylvania, USA., Watts S; GSK, Stevenage, UK., Weinblatt ME; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts, USA.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2023 Dec; Vol. 82 (12), pp. 1516-1526. Date of Electronic Publication: 2023 Sep 12.